Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis

CONTEXT: Considerable advances have been made in the first-line treatment of metastatic renal cell carcinoma (mRCC), with immunotherapy-based combinations including immunotherapy-tyrosine kinase inhibitors (IO-TKIs) and dual immunotherapy (IO-IO) favored. A lack of head-to-head clinical trials compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosma, Nicholas A., Warkentin, Matthew T., Gan, Chun Loo, Karim, Safiya, Heng, Daniel Y.C., Brenner, Darren R., Lee-Ying, Richard M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review – Kidney Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792068/
https://www.ncbi.nlm.nih.gov/pubmed/35128482
http://dx.doi.org/10.1016/j.euros.2021.12.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792068/
https://www.ncbi.nlm.nih.gov/pubmed/35128482
http://dx.doi.org/10.1016/j.euros.2021.12.007

Ejemplares similares